Semisolid formulations containing dimethyl sulfoxide and alpha-tocopherol for the treatment of extravasation of antiblastic agents.
The topical treatment with dimethyl sulfoxide (DMSO) and/or alpha-tocopherol (alpha-T) is widely used in order to prevent the local complications of extravasation of cytostatic drugs and protect patients against skin ulceration. Till now, DMSO and alpha-T have been mainly used in solution. The goal of this study was to formulate semisolid preparations for cutaneous application differing in the hydrophilic and lipophilic properties and containing DMSO and alpha-T in combination. With respect to solutions, the use of semisolid preparations containing DMSO and alpha-T could be advantageous in patients having extravasation as DMSO and alpha-T can remain in contact with the skin over an extended period of time. As a consequence, the action of the active principles can be limited specifically on the injured skin area, reducing the cutaneous irritative effects of DMSO. The following types of semisolid formulations containing 50% m/m DMSO and 2.5% m/m alpha-T were prepared: hydrophilic ointment, o/w emulsion, hydrophilic gel and lipophilic gel. The ex vivo skin permeation of DMSO and alpha-T was evaluated by using modified Franz's diffusion cells and human stratum corneum and epidermis (SCE) as a membrane. The permeated and retained amounts of DMSO and alpha-T were determined. The oleogel preparation, the hydrophilic gel and the o/w emulsion were uniform in colour and aspect, without any evidences of phase separation over the period of the study. Hydrophilic ointments were discarded as they showed phase separation after 12 h. All formulations had a different behaviour in terms of skin permeability. In particular, hydrogel and o/w emulsion showed the best control on the drug release considering the interactions of the vehicle components with the SCE and the drugs partition between the vehicle and the SCE. The DMSO permeated amount after 24 h was 4.1 mg/cm(2) for hydrogel and 2.5 mg/cm(2) for emulsion while the permeated amount of pure DMSO after 24 h was 47.5 mg/cm(2). Therefore, aiming to reduce side effects after the topical application of the antidotes DMSO and alpha-T, these results suggested that hydrogel and o/w emulsion could be considered the most promising formulations for further clinical evaluations in managing of extravasation of anthracyclines.
Casiraghi
Antonella
A
Istituto di Chimica Farmaceutica e Tossicologica Pietro Pratesi, Università degli Studi di Milano, Viale Abruzzi, 42, 20131 Milan, Italy. antonella.casiraghi@unimi.it
Ardovino
Paola
P
Minghetti
Paola
P
Botta
Cinzia
C
Gattini
Arrigo
A
Montanari
Luisa
L
D000287:Administration, Topical; D018943:Anthracyclines / Q000378:metabolism*; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D004121:Dimethyl Sulfoxide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004655:Emulsions; D005119:Extravasation of Diagnostic and Therapeutic Materials / Q000188:drug therapy*; D005260:Female; D006801:Humans; D012867:Skin / Q000187:drug effects / Q000378:metabolism*; D012883:Skin Ulcer / Q000517:prevention & control; D024502:alpha-Tocopherol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D018943:Anthracyclines; D000975:Antioxidants; D004655:Emulsions; D024502:alpha-Tocopherol; D004121:Dimethyl Sulfoxide